Weill Cornell Medicine Feb 11 2026 The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug. Diabetic retinopathy develops when chronically high blood sugar damages the blood vessels lining the back of the eye and affects nearly 10